Objective@#The aim of the study is to compare the diagnostic value of multiparametric transrectal ultrasound(TRUS) and
multiparametric magnetic resonance imaging (MRI) in
prostate cancer.@*
Methods@#The clinical data of 102
patients who received multiparametric TRUS (including conventional transrectal ultrasound,
shear wave sonoelastography and contrast enhanced ultrasound),
multiparametric MRI(including T2 weighted
diffusion weighted, and dynamic contrast enhanced MRI) and
laboratory tests from April 2016 to May 2018 were retrospectively analyzed. The average age was 66.1 years old, ranging 38.0-85.0 years old. The average PSA was 30.1 ng/ml, ranging 0.4-227.0 ng/ml. The average PSAD was 0.67 ng/ml2, ranging 0.02-4.27 ng/ml2. The
pathology results from TRUS guided
biopsy or surgical operation were chosen as
gold standard. Diagnostic performance including
sensitivity,
specificity,
positive predictive value(PPV),
negative predictive value(NPV), accuracy and area under the
receiver operating characteristic curve(AUROC)of multiparametric TRUS and
multiparametric MRI in
prostate cancer were analyzed.@*Results@#There were 62
prostate cancer and 40 BPH
patients in our study. Parallel multiparametric TRUS diagnosed 63
prostate cancer and 39 BPH, and
multiparametric MRI diagnosed 75
prostate cancer and 27 BPH. The
sensitivity,
specificity and accuracy of parallel multiparametric TRUS were 98.4%, 70.0% and 87.3%, respectively. And those of
multiparametric MRI were 95.2%, 60.0% and 81.4%, respectively. The AUROC of parallel multiparametric TRUS and
multiparametric MRI were 0.842 and 0.776, with no significant differences(P=0.208).@*Conclusion@#The diagnostic value of multiparametric TRUS was not inferior to
multiparametric MRI in
prostate cancer.